- Home
- Aesthetic gynaecology
- Intimate dryness and discomfort in menopause
- Vaginal dryness in the menopause
Vaginal dryness in the menopause: treatments with and without hormones
Lubricants, moisturisers, vaginal oestrogen, prasterone, ospemifene, systemic therapy, laser: what the evidence says about each option and who it is for.
Quando existir, entra aqui e também no cartão da página do blog.
In this article
Vaginal dryness is one of the most common symptoms of the menopause and, unlike hot flushes, it tends to persist or worsen over the years (NAMS, 2020). Fortunately, there are several treatment options, with and without hormones, and most women find one that works for them.
This article compares the options available, what the evidence says about each and who they are best suited to.
Three ideas to remember.
Fica por baixo do resumo, se existir uma segunda foto.
Treatments without hormones
Lubricants
They are used at the time of intercourse to reduce friction and pain. They work immediately, but the effect is temporary and they do not treat everyday dryness (NAMS, 2020).
- Water-based: versatile, compatible with condoms and sex toys; they dry out more quickly.
- Silicone-based: they last longer and are useful for marked dryness.
- To avoid: fragrances, warming effects and, in water-based ones, very high osmolality (Edwards and Panay, 2016).
Vaginal moisturisers
They are used 2 to 3 times a week, regardless of intercourse. They adhere to the lining and retain water, relieving dryness, burning and discomfort (NAMS, 2020).
- Moisturisers containing hyaluronic acid improved dryness in clinical trials (Chen et al., 2013).
- In a randomised trial, symptoms improved to a similar degree with vaginal moisturiser, vaginal oestrogen and placebo gel after 12 weeks (Mitchell et al., 2018), so that trial showed no advantage of one over the others. Moisturisers help with comfort, but they do not act on the hormonal cause; the recommendations keep low-dose vaginal oestrogen as an effective option when they are not enough (NAMS, 2020).
Pelvic floor physiotherapy
It improves circulation in the area, teaches you to relax the muscles and helps when there is pain during intercourse. Early studies in postmenopausal women showed an improvement in symptoms (Mercier et al., 2019).
Sexual activity
Regular sexual activity, with or without a partner, can help maintain vaginal elasticity and circulation, according to NAMS recommendations (NAMS, 2020). Vaginal dilators are an option for those who do not have intercourse and want to maintain elasticity.
Vaginal laser and radiofrequency
These are energy-based treatments carried out in the clinic. The results of studies are contradictory: in a rigorous trial, the CO2 laser was not superior to a sham treatment (Li et al., 2021). Scientific societies consider that there is not yet enough evidence to recommend them as a first option (NAMS, 2020).
Treatments with hormones
Low-dose vaginal oestrogen
It is the treatment with the most evidence for menopausal vaginal dryness (NAMS, 2020, Lethaby et al., 2016). It comes as a cream, pessaries, vaginal tablets, gel and vaginal ring.
- It restores the thickness and elasticity of the lining, lowers the pH and re-establishes the flora.
- Absorption into the blood is minimal at low doses, and large studies have not shown an increased risk of breast cancer, endometrial cancer, stroke or thrombosis (NAMS, 2020).
- In general, there is no need to add progesterone (NAMS, 2020).
- It usually starts with daily application for about two weeks and then moves to 2 to 3 times a week.
Vaginal prasterone (DHEA)
It is applied daily in the vagina and converted locally into oestrogens and androgens. In placebo-controlled trials, it improved dryness and pain during intercourse (Labrie et al., 2016).
Ospemifene
It is an oral tablet that acts like oestrogen on vaginal tissue without being a hormone. In placebo-controlled trials, it reduced pain during intercourse (Portman et al., 2013). It may be an option for women who do not want to, or cannot, use vaginal treatments, but it has contraindications that need to be assessed, such as a history of thrombosis.
Systemic hormone therapy
Oestrogen tablets, patches or gels applied to the skin also improve vaginal dryness. But when dryness is the only symptom, local treatment is preferred. Systemic therapy is mainly justified when there are also hot flushes or other menopausal symptoms, and the decision depends on age, the time since the menopause and individual risk (NAMS, 2022).
Some women on systemic therapy continue to have dryness and benefit from adding a local treatment (NAMS, 2020).
Quick comparison
| Option | Contains hormones | Needs a prescription | Restores the lining | For whom |
|---|---|---|---|---|
| Lubricant | no | no | no | all women, during intercourse |
| Vaginal moisturiser | no | no | no | mild symptoms, or those who do not want hormones |
| Vaginal oestrogen | yes, low dose | yes | yes | moderate to severe symptoms |
| Vaginal prasterone | yes, local | yes | yes | alternative to vaginal oestrogen |
| Ospemifene | not a hormone, but acts like oestrogen in the vagina | yes | yes | pain during intercourse, without vaginal treatment |
| Systemic therapy | yes | yes | yes | when there are other menopausal symptoms |
| Pelvic physiotherapy | no | no | no | associated pain and muscle tension |
How to choose
- Mild symptoms, only during intercourse: start with lubricant.
- Dryness in everyday life too: add a regular vaginal moisturiser.
- No improvement after a few months, or severe symptoms: talk to your doctor about vaginal oestrogen or another prescription option.
- History of breast cancer: start with non-hormonal options and decide the rest with the oncology team (Faubion et al., 2018).
- Pain that persists despite treatment: consider pelvic physiotherapy and reassess other causes.
Many women combine options, for example vaginal oestrogen and lubricant during intercourse.
When to see a doctor
Any vaginal bleeding after the menopause should be assessed by a doctor.
If you have any doubts about the symptoms, call SNS 24 (808 24 24 24). In case of heavy bleeding, chest pain, sudden shortness of breath, pain and swelling in one leg or signs of a stroke, call 112.
At Luxmed Clinic
At the gynaecological aesthetics consultation, we assess the symptoms, the medical history and the medication, examine the vulva and the vagina and explain the options with and without hormones, along with what the evidence says about each one.
The decision is made together with you, with a plan tailored to your preferences and your health history. When necessary, we work together with your own doctor or oncologist.
Talk to us
The assessment is a conversation, with no obligation. Tell us what concerns you and our team will reply.
This article is for information only and does not replace a medical assessment. Results vary from person to person.
Frequently asked questions
What is the best treatment for vaginal dryness in the menopause?
It depends on the severity of the symptoms and on each woman's preferences. Low-dose vaginal oestrogen has the most evidence, but lubricants and moisturisers are enough for many women with mild symptoms.
Are there treatments for vaginal dryness without hormones?
Yes: lubricants, vaginal moisturisers, pelvic physiotherapy and, in selected cases, ospemifene, which is not a hormone.
Is vaginal oestrogen the same as menopausal hormone therapy?
No. Low-dose vaginal oestrogen acts mainly locally, with minimal absorption. Systemic therapy delivers hormones to the whole body and has different indications and risks.
Do vaginal moisturisers work?
They relieve dryness and discomfort in many women, but they do not act on the hormonal cause. If symptoms persist, the doctor may suggest low-dose vaginal oestrogen.
How long does treatment take to work?
Lubricants work immediately. Moisturisers and vaginal oestrogen need a few weeks, and the full effect can take 2 to 3 months.
Do I have to stay on treatment for ever?
Because the lack of oestrogen persists, symptoms tend to come back when treatment stops. It can be continued for as long as there is benefit, with periodic review.
Does vaginal laser solve dryness?
The evidence is still contradictory, and it is not recommended as a first option.
Scientific references 11
- The North American Menopause Society. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92. Guideline
- Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151-61. Artigo
- Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013;10(6):1575-84. Artigo
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178(5):681-90. Artigo
- Mercier J, Morin M, Zaki D, et al. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: a single-arm feasibility study. Maturitas. 2019;125:57-62. Artigo
- Li FG, Maheux-Lacroix S, Deans R, et al. Effect of fractional carbon dioxide laser vs sham treatment on symptom severity in women with postmenopausal vaginal symptoms: a randomized clinical trial. JAMA. 2021;326(14):1381-9. Artigo
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500. Revisão Cochrane
- Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-56. Artigo
- Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623-30. Artigo
- The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-94. Guideline
- Faubion SS, Larkin LC, Stuenkel CA, et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause. 2018;25(6):596-608. Guideline
Keep exploring


